NASDAQ$ALNY
Alnylam Pharmaceuticals Inc · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
Alnylam Pharmaceuticals reported strong second quarter 2026 financial results driven by robust growth in AMVUTTRA product sales.
Total revenues reached $1.29 billion for the quarter, reflecting a 67% increase year-over-year primarily from AMVUTTRA net product revenues of $1.01 billion. The company achieved net income of $164.5 million and operating income of $231.4 million, demonstrating continued commercial momentum across its TTR and rare disease franchises.
- AMVUTTRA net product revenues grew 106% year-over-year to $1.01 billion, fueled by strong uptake in ATTR-CM.
- Total TTR franchise revenues reached $1.03 billion, while the rare disease franchise contributed $142 million.
- Net income of $164.5 million and operating income of $231.4 million reflect improved profitability.
- Cash and cash equivalents stood at $1.71 billion at quarter end, supporting ongoing pipeline advancement.
Headline financials
Revenue & EPS history
Alnylam · Revenue · Quarterly
$1.29B
Revenue by segment
Alnylam · $1.17B total across 4 segments · Q2 2026
- AMVUTTRA$1.01B—86.3%
- GIVLAARI$89.8M—7.7%
- OXLUMO$52.1M—4.4%
- ONPATTRO$18.5M—1.6%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.5%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+15.4%
Q2 2025
Best reaction
-16.9%
Q2 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +4.3% | -0.0% | +0.2% | |
| Q4 2025 | -4.3% | +3.2% | -2.8% | |
| Q3 2025 | -6.7% | -12.1% | -6.3% | |
| Q2 2025 | +15.4% | +23.3% | +31.4% | |
| Q1 2025 | -3.1% | +2.5% | +15.7% | |
| Q4 2024 | -0.4% | -6.0% | -9.1% | |
| Q3 2024 | -2.7% | -5.8% | -10.1% | |
| Q2 2024 | +14.6% | +10.6% | +10.6% | |
| Q1 2024 | +1.6% | +2.9% | -1.0% | |
| Q4 2023 | -10.4% | -8.8% | -9.1% | |
| Q3 2023 | +6.6% | +8.4% | +9.2% | |
| Q2 2023 | -0.8% | -1.2% | +7.6% | |
| Q1 2023 | +6.3% | +4.2% | -2.9% | |
| Q4 2022 | -5.6% | -4.8% | -5.5% | |
| Q3 2022 | +1.7% | +6.0% | +5.8% | |
| Q2 2022 | +0.0% | +0.0% | +48.6% | |
| Q1 2022 | -13.9% | -7.8% | -17.5% | |
| Q4 2021 | -0.4% | +1.3% | +2.4% | |
| Q3 2021 | -16.5% | -12.3% | -1.4% | |
| Q2 2021 | +3.1% | +9.7% | +12.5% | |
| Q1 2021 | -2.0% | -8.3% | -1.1% | |
| Q4 2020 | -3.8% | -6.3% | -13.4% | |
| Q3 2020 | -6.3% | -10.4% | -7.1% | |
| Q2 2020 | -4.6% | -9.2% | -18.4% | |
| Q1 2020 | +0.2% | +0.8% | -9.7% | |
| Q4 2019 | +3.2% | +6.5% | -6.7% | |
| Q3 2019 | +4.3% | +5.5% | +34.2% | |
| Q2 2019 | +12.7% | +13.1% | +16.4% | |
| Q1 2019 | -7.6% | -17.1% | -24.4% | |
| Q4 2018 | -5.0% | +2.5% | +1.8% | |
| Q3 2018 | -15.3% | -21.3% | -13.8% | |
| Q2 2018 | -3.0% | -0.6% | +29.8% | |
| Q1 2018 | +2.6% | +6.8% | +11.8% | |
| Q4 2017 | -5.1% | -2.3% | +9.0% | |
| Q3 2017 | +1.4% | +7.3% | -1.4% | |
| Q2 2017 | -6.8% | -2.2% | -9.5% | |
| Q1 2017 | -4.1% | +1.5% | +31.2% | |
| Q4 2016 | +11.1% | +12.7% | +25.4% | |
| Q3 2016 | -15.1% | -2.0% | +12.4% | |
| Q2 2016 | +9.9% | +7.1% | -3.1% | |
| Q1 2016 | -9.3% | — | — | |
| Q4 2015 | +4.5% | — | — | |
| Q3 2015 | +5.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +6.7% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +3.2% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +5.3% | — | — | |
| Q4 2013 | -2.1% | — | — | |
| Q3 2013 | -11.2% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.5% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -1.5% | — | — | |
| Q1 2012 | -9.0% | — | — | |
| Q4 2011 | -9.6% | — | — | |
| Q3 2011 | +1.5% | — | — | |
| Q2 2011 | -14.9% | — | — | |
| Q1 2011 | +2.3% | — | — | |
| Q4 2010 | +13.2% | — | — | |
| Q3 2010 | +2.4% | — | — | |
| Q2 2010 | -0.9% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro